This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Digestive System Disease Animal Model Development Service
Introduction
Boost the development of animal models for digestive system disorders and your preclinical research procedure! Do you find it difficult to test new medications for gastrointestinal, hepatic, or pancreatic illnesses or to establish disease pathways? High-quality, validated animal models, a variety of construction methods, and strong analytical assistance are all offered by BioVenic's extensive digestive system disease animal model development services. We help streamline your preclinical evaluation process, overcoming the limitations of complex in vivo studies.
BioVenic Digestive System Disease Animal Model Development Services
BioVenic Digestive System Disease Animal Model Construction
BioVenic offers extensive expertise in developing both standardized and customized digestive system disease animal models. The major disease types in our portfolio range from hepatic diseases, which include NAFLD/NASH and liver fibrosis, to gastrointestinal inflammation, which includes IBD, gastritis, and ulcers, as well as pancreatitis. The experts at BioVenic are also proficient in the development of custom models according to your research needs, where the pathology of the model is matched with the desired research endpoints. Investigating distinct disease subgroups or new treatment targets requires this customized service.
Digestive System Disease Animal Model Validation and Characterization
Model validation is paramount to ensure the successful replication of the human condition and the reliability of your study data. BioVenic utilizes a range of established techniques to confirm the pathological state of the developed animal models. Common validation methods include:
Histopathology and Immunohistochemistry: Measurement of specific proteins, organ damage, and inflammation levels such as H&E for mucosal damage or liver fibrosis.
Biochemical Marker Analysis: Quantifying important metabolites and serum or tissue enzymes.
Macroscopic Scoring: Measurement of disease state in an animal model using specific scoring criteria for disease state or disease activity such as the illness Activity Index (DAI) for IBD animal models.
Digestive System Disease Animal Model Sample Collection
BioVenic provides expert, high-quality biospecimen collection services tailored to your downstream analytical needs. Our experts guarantee the consistent and careful gathering of:
Tissue Samples: The liver, stomach, small intestine, colon, and pancreas require specific methods of collection and preservation through snap-freezing and formalin fixation.
Biofluids: The precise collection process yields accurate specimens of urine, bile, feces, serum, plasma, and whole blood.
Cell Isolation: The process involves achieving primary cell isolation which includes heptocytes and immune cells for ex vivo analysis.
Experimental Studies in Digestive System Disease Animal Models
Leveraging our established models, BioVenic offer a range of preclinical, non-GLP experimental research services, including:
Efficacy and Mechanism of Action Studies: The research aims to assess how your compounds affect living organisms and which biological pathways they attack.
Pharmacodynamics (PD) Evaluation: To assess how your candidate substance impacts living organisms throughout different time periods.
Toxicology and Safety Assessment: Begins with an assessment of how the compound performs during its initial in vivo test phase.
Biomarker Discovery and Validation.
Explore BioVenic’s investigative modalities:
- Animal Behavioral Analysis
- Animal Histopathology Service
- Preclinical Animal Pharmacodynamics (PD) Study
- Preclinical Animal Pharmacokinetics (PK) Study
- Animal Cell Biology Service
- Animal lmaging Service
- Omics Solution in Animal Nutrition and Metabolism
- Animal Nutrition and Metabolism Analysis
BioVenic’s animal digestive system disease model development related services also include:
- Animal Nutrition and Metabolism In Vitro Model Development
- Metabolic Disorder Animal Model Development
- Diet-induced Animal Model Development
- Genome-edited Animal Model Development
- Chemically-induced Animal Model Development
- Surgically-induced Animal Model Development
Development Workflow for a Digestive System Disease Animal Model
Fig. 1 BioVenic Digestive System Disease Animal Model Development Workflow (BioVenic AI)
Digestive System Disease Animal Model Applications Overview
BioVenic’s digestive system disease animal models are crucial for various preclinical applications, from mechanism elucidation to compound screening.
Table. 1 Common Digestive System Disease Animal Models and Applications
| Disease Model | Animal Species | Modeling Method | Chemical Inducing Agent / Surgical Method | Key Applications |
|---|---|---|---|---|
| Gastric Acid Secretion & Gastric Ulcer Disease Models | ||||
| Gastric Acid Secretion Model | Rat | Surgery/Chemical | Pylorus ligation, Histamine | Screening of H2 receptor antagonists and Proton Pump Inhibitors (PPIs); studying acid secretion mechanism. |
| Acute Gastric Ulcer (AGU) | Rat, Mouse | Chemical/Surgery/Stress | Ethanol, Acetylsalicylic acid, Water immersion restraint stress, Pylorus ligation | Testing anti-ulcer drugs (e.g., mucosal protectants, acid suppressants); safety assessment of NSAIDs. |
| Chronic Gastric Ulcer (CGU) | Mouse | Chemical | Acetic acid cauterization method | Evaluating long-term healing potential of anti-ulcer medications; studying ulcer recurrence. |
| Chronic Atrophic Gastritis Model | Rat, Mouse | Chemical/Surgery/Compound | Multi-factor stimulation (Ammonia water, Sodium salicylate, etc.); MNNG; H. pylori gavage; Gastrojejunostomy | Researching the progression of pre-cancerous lesions; testing prophylactic agents and anti-fibrotic therapies. |
| Gastritis | Rat, Mouse | Chemical | Ethanol gavage; Gavage of ox bile and glycerol mixture | Evaluating anti-inflammatory and mucosal protective agents for acute gastritis. |
| Duodenal Ulcer (DU) | Rat, Mouse | Chemical | Acetic acid, Cysteamine | Screening of acid suppressants and mucosal protective agents specifically for the duodenum. |
| Inflammatory Bowel Disease (IBD) | ||||
| Ulcerative Colitis (UC) | Rat, Mouse | Chemical | TNBS, DNBS, DSS, Oxazolone (OXZ) | Evaluating anti-inflammatory and immunosuppressive drugs; studying gut microbiota-inflammation interactions; testing compounds for mucosal repair. |
| Crohn's Disease (CD) | Rat | Chemical | TNBS, DNCB combined with Acetic acid | Testing compounds targeting Th1/Th17 pathways; studying transmural inflammation and fibrosis associated with CD. |
| Gastrointestinal Motility Disorder Models | ||||
| Functional Dyspepsia | Rat, Mouse | Stress/Chemical/Compound | Chronic unpredictable mild stress; Iodoacetamide gavage | Evaluating prokinetic agents; assessing drugs targeting visceral hypersensitivity and the gut-brain axis. |
| Pancreatic Disease Models | ||||
| Acute Pancreatitis (AP) | Rat, Mouse | Surgery/Chemical/Compound | Pancreatic duct ligation; Retrograde sodium taurocholate; L-arginine; Cerulein pretreatment | Investigating mechanisms of pancreatic autodigestion and inflammation; evaluating compounds to reduce inflammation and necrosis. |
| Chronic Pancreatitis (CP) | Rat | Chemical/Surgery | TNBS induced chronic pancreatic fibrosis; Pancreatic duct ligation; Repeated L-arginine injection | Studying mechanisms of pancreatic fibrosis; testing anti-fibrotic and pain management compounds. |
| Liver Disease Models | ||||
| Liver Fibrosis (HF) | Rat, Mouse | Chemical/Surgery | CCl4, Dimethylnitrosamine, Hepatic artery ligation | Screening anti-fibrotic drugs; investigating the role of Hepatic Stellate Cells (HSCs) and TGF-beta signaling. |
| Liver Cirrhosis (LC) | Rat, Mouse, Rabbit, Dog | Chemical/Surgery | CCl4, Biliary tract ligation | Studying complications of portal hypertension and ascites; evaluating compounds for late-stage liver disease. |
| Liver Failure (LF) / Acute Liver Injury | Rat, Mouse | Chemical | APAP, ConA, 17alpha-Ethinylestradiol, alpha-Naphthylisothiocyanate | Toxicology screening and studying hepatotoxicity mechanisms; testing hepatoprotective agents and anti-oxidants. |
| Non-Alcoholic Fatty Liver (NAFLD) | Rat | Diet/Chemical | High-fat diet combined with CCl4 | Evaluating drugs for fat accumulation (steatosis); studying the progression to NASH and insulin resistance. |
| Biliary Tract Disease Models | ||||
| Gallstones (GS) / Gallbladder Stones | Rat, Mouse | Diet/Surgery | Lithogenic diet induced cholesterol stones; Common bile duct ligation | Researching gallstone formation mechanisms; screening cholelitholytic (stone-dissolving) agents. |
Advantages of BioVenic Digestive System Disease Animal Model Development Service
Versatility in Model Construction
BioVenic combines expertise from various model-building methods which include chemical induction, dietary manipulation, surgical techniques and genetic modification. We possess multiple research capabilities which enable us to choose and implement the most suitable scientific research model that translates to your specific compound needs.
Project Customization and Scientific Rigor
Every project is unique. To create a customized study plan, BioVenic's top experts carefully examine your experimental objectives, early data, and chemical profile. In order to ensure the scientific rigor necessary to produce significant and repeatable data that supports your scientific results, we choose the best animal model, administration route, and experimental endpoints.
Integrated Analytical and Detection Services
Beyond model construction, BioVenic offers a powerful, integrated platform for validation and sample analysis. This includes comprehensive histopathology services, advanced biochemical indicator analysis, and the capability to perform sophisticated molecular techniques (e.g., ELISA, western blot, gene expression analysis) on collected samples. Our comprehensive detection capability ensures a seamless transition from model development to final data delivery.
Case Study: Standardized CCl4-Induced Liver Fibrosis & Efficacy Evaluation
Our platform offers a highly reproducible liver fibrosis model via standardized intraperitoneal CCl4 induction. We employ a "triple-threat" validation protocol to ensure modeling integrity: biochemical profiling (tracking 3-5x elevations in serum ALT/AST), histopathological gold standards (Masson’s Trichrome and Sirius Red staining for collagen bridging/pseudolobule quantification), and molecular verification of HSC activation via alpha-SMA and Col1a1 expression. Utilizing this robust system, we provide comprehensive efficacy assessments for anti-fibrotic candidates, delivering detailed mechanistic insights into the TGF-beta1/Smad signaling pathway and oxidative stress modulation (MDA/SOD assays).
Fig. 2 Mangiferin relieves liver injury induced by CCl41
FAQs
Q: Which animal species is best for a liver fibrosis study?
A: The scale and endpoint determine the decision. Mice and rats (e.g., CCl4 or TAA induced) are the most cost-effective for mechanistic studies and high-throughput screening. For bigger-scale surgical treatments or specific PK/PD requirements, larger animals may be considered.
Q: Do you offer GLP-compliant studies?
A: To expedite early-stage drug screening, proof-of-concept, and mechanism elucidation before formal regulatory submission-required investigations, we concentrate on non-GLP preclinical trials.
Q: How do you ensure the chosen model is appropriate for my compound?
A: The BioVenic team first analyzes your compound's MoA and compare it against the known pathology and key signaling pathways of available animal models. For instance, we give preference to models with strong inflammatory indicators, such as the TNBS-induced colitis model, if your medication addresses inflammation.
Q: Can you validate a model that we have already developed in-house?
A: Yes. We can provide independent validation services, including blinded histopathological scoring, specific biochemical assays, and molecular analysis on your existing model's tissues or biofluids to confirm disease phenotype.
Contact Us
By offering a range of model construction choices (chemical, surgical, genetic), comprehensive validation, and integrated preclinical services, BioVenic reduces the complexity and time required for your in vivo investigations. To advance your preclinical research, contact us right now to discuss your unique digestive system illness model requirements and obtain a personalized quote!
Reference
- Zhang, Lijun, et al. "Mangiferin relieves CCl4-induced liver fibrosis in mice." Scientific Reports 13.1 (2023): 4172. https://doi.org/10.1038/s41598-023-30582-3. Distributed under Open Access license CC BY 4.0. Without modification.